BACKGROUND: To ascertain which demographic, clinical, and microbiological factors might affect clinical outcomes of @entity1 with @entity6 , excluding known @entity4034 , by analysing Clinical Assessment Program and Teflaro   Utilization Registry study data of @entity1 treated with @entity40629 fosamil. METHODS: At participating study centres, we collected data by randomized selection and chart review, including @entity1 demographics, co-morbidities, infecting pathogens, antibiotic use, surgical interventions, and clinical response. Evaluable @entity1 were those with data sufficient to determine clinical outcome. Clinical success was defined as clinical cure with no use of other antibiotics or clinical improvement with a switch to oral antibiotic therapy at the end of intravenous @entity40629 fosamil treatment. RESULTS: Among 201 @entity1 (mean age 61.7  years, mean body mass index 33.2 and 57% male @entity1 ), 40% had @entity1095 . Prior antibiotic therapy had been given to 161 (80%) of the @entity1 , most commonly with @entity2176 and/or @entity3400 - @entity7120 . @entity1 received @entity40629 fosamil for mean duration of 6.1  days (range 1-30), as monotherapy in 130 (65%) @entity1 and concurrently with other antibiotics in 71 (35%). Bacterial pathogens were identified in 114 (57%) of the @entity1 ; @entity3256 -resistant @entity794 and @entity3256 -sensitive @entity794 were isolated from 56 (49%) and 28 (25%) of culture-positive @entity1 respectively. Clinical success was noted in 81% of @entity1 and was not significantly associated with co-morbidities, pathogen type, or need for surgical intervention. CONCLUSIONS: @entity40629 fosamil treatment of @entity6 was associated with high clinical success, including inpatients with @entity28 , co-morbidities, or @entity3256 -resistant @entity794 or @entity325 or requiring surgical intervention. Copyright    2014 John Wiley _ Sons, Ltd.

@entity40629 fosamil for treatment of XXXX : the CAPTURE study experience.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity1095 :: ('MESH:D016491', 'Disease') :: ['peripheral vascular disease'] @entity3256 :: ('MESH:D008712', 'Chemical') :: ['methicillin'] @entity2176 :: ('MESH:D014640', 'Chemical') :: ['vancomycin'] @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetic foot infections'] @entity28 :: ('MESH:D009765', 'Disease') :: ['obesity'] @entity4034 :: ('MESH:D010019', 'Disease') :: ['osteomyelitis'] @entity40629 :: ('MESH:C490727', 'Chemical') :: ['ceftaroline', 'Ceftaroline'] @entity794 :: ('1280', 'Species') :: ['Staphylococcus aureus', 'S. aureus'] @entity7120 :: ('MESH:C043265', 'Chemical') :: ['tazobactam'] @entity325 :: ('MESH:D060085', 'Disease') :: ['mixed infections'] @entity3400 :: ('MESH:D010878', 'Chemical') :: ['piperacillin']
@entity6 :: (MESH:D003920,Disease) :: ['diabetic foot infections']
